Table.
Cancer diagnoses made through the 2-week-wait pathway for 2013–16
|
Proportion of annual cancer diagnoses that are 2-week-wait diagnoses |
Proportion by age group (years) |
Proportion by cancer stage |
Diagnostic conversion rate |
Estimated annual 2-week-wait referrals |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | ≥80 | Stage I | Stage II | Stage III | Stage IV | Stage I–III | Proportion of any cancer | Proportion of cancers in tumour referral group | |||
| Bladder | 3654/8524 (42·9%) | 0·3% | 2·1% | 7·4% | 23·4% | 36·2% | 30·6% | 51·9% | 29·1% | 6·7% | 12·3% | 87·7% | 16·9% | 98·2% | 21 624 |
| Brain | 140/8102 (1·7%) | 8·7% | 8·4% | 16·4% | 31·2% | 25·2% | 10·1% | N/A | N/A | N/A | N/A | N/A | 1·0% | 100·0% | 13 982 |
| Breast | 22 678/41 845 (54·2%) | 6·1% | 19·1% | 16·2% | 16·3% | 20·5% | 21·8% | 31·2% | 50·9% | 13·0% | 4·9% | 95·1% | 4·9% | 99·3% | 462 822 |
| Cervix | 471/2128 (22·1%) | 16·6% | 15·8% | 18·1% | 19·7% | 17·3% | 12·4% | 29·3% | 40·1% | 15·0% | 15·6% | 84·4% | 3·1% | 97·4% | 15 183 |
| Colorectal | 10 620/32 979 (32·2%) | 0·8% | 3·1% | 13·0% | 21·5% | 33·0% | 28·5% | 15·4% | 28·2% | 32·5% | 23·9% | 76·1% | 2·8% | 78·4% | 379 272 |
| Kidney | 2459/8764 (28·1%) | 2·3% | 8·1% | 17·7% | 27·8% | 27·5% | 16·7% | 45·3% | 11·4% | 21·8% | 21·6% | 78·4% | 16·9% | 98·2% | 14 551 |
| Larynx | 887/1850 (48·0%) | 0·5% | 5·2% | 19·4% | 33·3% | 28·2% | 13·4% | 36·6% | 19·3% | 17·8% | 26·3% | 73·7% | 2·9% | 74·0% | 30 599 |
| Liver | 683/4712 (14·5%) | 0·7% | 1·9% | 10·1% | 25·2% | 34·3% | 27·7% | 7·6% | 10·6% | 15·6% | 66·1% | 33·9% | 5·7% | 85·9% | 11 989 |
| Lung | 10 343/36 668 (28·2%) | 0·3% | 2·2% | 10·2% | 30·2% | 35·8% | 21·3% | 15·4% | 9·9% | 27·9% | 46·8% | 53·2% | 10·9% | 93·7% | 94 893 |
| Melanoma* | 7642/12 110 (63·1%) | 10·4% | 14·2% | 17·8% | 23·0% | 20·3% | 14·3% | 71·5% | 20·4% | 6·5% | 1·6% | 98·4% | 4·4% | 98·1% | 173 673 |
| Oesophagus | 3339/7427 (45·0%) | 0·4% | 3·0% | 12·9% | 29·0% | 31·0% | 23·8% | 7·4% | 16·1% | 41·2% | 35·3% | 64·7% | 5·7% | 85·9% | 58 571 |
| Oral cavity | 1161/2629 (44·1%) | 2·9% | 9·7% | 22·4% | 29·4% | 20·9% | 14·8% | 27·3% | 15·8% | 10·4% | 46·5% | 53·5% | 2·9% | 74·0% | 40 022 |
| Oropharynx | 1710/2905 (58·9%) | 1·4% | 12·1% | 34·7% | 33·8% | 14·2% | 3·8% | 2·8% | 6·1% | 13·4% | 77·6% | 22·4% | 2·9% | 74·0% | 58 960 |
| Ovary | 2142/6398 (33·5%) | 4·2% | 8·4% | 21·0% | 28·9% | 25·4% | 12·0% | 31·9% | 7·8% | 41·7% | 18·6% | 81·4% | 3·1% | 97·4% | 69 112 |
| Pancreas | 1594/8260 (19·3%) | 0·2% | 2·1% | 9·4% | 26·0% | 36·1% | 26·1% | 5·8% | 14·7% | 13·7% | 65·8% | 34·2% | 5·7% | 85·9% | 27 962 |
| Prostate | 19 272/40 834 (47·2%) | 0·0% | 0·9% | 9·6% | 32·9% | 38·2% | 18·2% | 27·9% | 21·6% | 26·0% | 24·5% | 75·5% | 16·9% | 98·2% | 114 037 |
| Stomach | 1654/5332 (31·0%) | 0·4% | 3·0% | 12·9% | 29·0% | 31·0% | 23·8% | 8·3% | 18·5% | 27·2% | 46·1% | 53·9% | 5·7% | 85·9% | 29 024 |
| Testis | 829/1355 (61·2%) | 61·7% | 22·4% | 10·9% | 3·4% | 1·2% | 0·4% | 86·6% | 7·8% | 3·1% | 2·5% | 97·5% | 9·0% | 75·0% | 9213 |
| Thyroid | 620/2673 (23·2%) | 28·3% | 19·0% | 18·1% | 15·1% | 12·2% | 7·3% | 44·4% | 10·0% | 19·0% | 26·7% | 73·3% | 2·9% | 74·0% | 21 388 |
| Uterus | 4390/7604 (57·7%) | 0·2% | 2·3% | 19·1% | 35·8% | 29·2% | 13·4% | 75·7% | 7·5% | 11·0% | 5·9% | 94·1% | 3·1% | 97·4% | 141 614 |
Data shown are proportion of all diagnoses made via 2-week-wait pathway, with a breakdown by cancers diagnosed via this pathway by age and cancer stage, diagnostic conversion rate, and average annual referrals. Diagnostic conversion rates reflect all diagnoses of invasive cancers (exceptions are that breast includes carcinoma in situ, skin excludes basal cell carcinomas, urology excludes pTa bladder tumours). N/A=not applicable.
*
Of the skin.